Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search

Other anticoagulants

Citations 1-10 of 91 total displayed.

Most recent content (2 Nov 2009):

Articles
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
John W. Eikelboom, Daniel J. Quinlan, and Martin O'Donnell
Circulation published November 2, 2009, doi:10.1161/CIRCULATIONAHA.109.872630 [Abstract]  

Past content (since Jan 2001):

Editorials
New Therapies for Stroke Prevention in Atrial Fibrillation: The Long Road to Enhanced Efficacy
Jane E. Freedman and Bernard J. Gersh
Circulation 2009;120:1024-1026; published online before print as doi:10.1161/CIRCULATIONAHA.109.893362 [Full text]  

Arrhythmia/Electrophysiology
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation 2009;120:1029-1035; published online before print as doi:10.1161/CIRCULATIONAHA.109.856120 [Abstract] [Full text]  

Articles
New Therapies for Stroke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy
Jane E. Freedman and Bernard J. Gersh
Circulation published September 9, 2009, doi:10.1161/CIRCULATIONAHA.109.893362 [Abstract]  

Articles
New Therapies for Stoke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy
Jane E. Freedman and Bernard J. Gersh
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.893362 [Abstract]  

Articles
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.856120 [Abstract]  

Coronary Heart Disease
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
APPRAISE Steering Committee and Investigators
Circulation 2009;119:2877-2885; published online before print as doi:10.1161/CIRCULATIONAHA.108.832139 [Abstract] [Full text]  

Articles
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
APPRAISE Steering Committee and Investigators
Circulation published May 26, 2009, doi:10.1161/CIRCULATIONAHA.108.832139 [Abstract]  

Editorials
Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome: Can Anything Be Done About It?
Theodore E. Warkentin and Mark A. Crowther
Circulation 2009;119:2420-2422, doi:10.1161/CIRCULATIONAHA.109.858316 [Full text]  

Editorials
Stopping the Hemorrhage: A New Baseline Bleeding Score Brings Us a Step Closer for Patients With Non–ST-Elevation Myocardial Infarction
Jeffrey L. Anderson
Circulation 2009;119:1846-1849, doi:10.1161/CIRCULATIONAHA.109.854281 [Full text]  

[Next page]
Pages: 1 2 3 4 5 6 7 8 9 10

* Subspecialty Collections Home

* Show  Other anticoagulants
 collections from other journals.

* Related collections:
 Anticoagulants
 Coumarins
 Heparin
 Other anticoagulants